Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 8721257, 12 pages
https://doi.org/10.1155/2017/8721257
Research Article

Garidisan: Improving the Quality of Ulcer Healing in Rats with Ulcerative Colitis

1Institute of Chinese Minority Traditional Medicine, Minzu University of China, Beijing 100081, China
2Department of Histology and Embryology, Xinxiang Medical University, Xinxiang, Henan 453003, China
3Key Laboratory of Chinese Minority Traditional Medicine, Minzu University of China, State Ethnic Affairs Commission and Ministry of Education, Beijing 100081, China

Correspondence should be addressed to Shu-Chun Li; moc.621@cslnosaj

Received 8 February 2017; Revised 21 May 2017; Accepted 6 June 2017; Published 8 August 2017

Academic Editor: José L. Rios

Copyright © 2017 Lin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Adams and P. H. Bornemann, “Ulcerative colitis,” American Family Physician, vol. 87, pp. 699–705, 2013. View at Google Scholar
  2. L. Lopetuso and A. Gasbarrini, “Ulcerative colitis,” Recenti Progressi in Medicina, vol. 107, pp. 297–308, 2016. View at Google Scholar
  3. O. H. Nielsen, T. Jess, J. T. Bjerrum, and J. B. Seidelin, “Ulcerative colitis,” Ugeskr Laeger, 176 pages, 2014. View at Google Scholar
  4. L. Roose, J. D'cunja, and L. Biedermann, “Ulcerative colitis,” Praxis, vol. 105, pp. 607–615, 2016. View at Google Scholar
  5. I. Kryczek, L. Wang, K. Wu, W. Li, E. Zhao, T. Cui et al., “Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma,” Oncoimmunology, vol. 5, Article ID 1105430, 2016. View at Google Scholar
  6. R. Akitake, H. Nakase, M. Tamaoki, S. Ueno, S. Mikami, and T. Chiba, “Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis,” Digestive Diseases and Sciences, vol. 55, no. 6, pp. 1781–1784, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kobayashi, S. Okamoto, T. Hisamatsu et al., “IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease,” Gut, vol. 57, pp. 1682–1689, 2008. View at Google Scholar
  8. E. J. Cho, J. S. Shin, Y. S. Noh et al., “Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis,” Journal of Ethnopharmacology, vol. 136, pp. 428–435, 2011. View at Google Scholar
  9. C. L. Wen, C. C. Chang, S. S. Huang, C. L. Kuo, S. L. Hsu, J. S. Deng et al., “Anti-inflammatory effects of methanol extract of Antrodia cinnamomea mycelia both in vitro and in vivo,” Journal of Ethnopharmacology, vol. 137, pp. 575–584, 2011. View at Google Scholar
  10. W. Blonski, A. M. Buchner, and G. R. Lichtenstein, “Treatment of ulcerative colitis,” Current Opinion in Gastroenterology, vol. 30, pp. 84–96, 2014. View at Google Scholar
  11. G. Fiorino, P. N. Cortes, P. Ellul et al., “Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study,” Clinical Gastroenterology and Hepatology, vol. 14, pp. 1426–1432, 2016. View at Google Scholar
  12. J. Cui, Z. R. Pang, D. LGM, L. BN, and L. WZH, “Clinical observation on Garidisan in 60 patients with ulcerative colitis,” Tianjin Journal of Traditional Chinese Medicine, vol. 29, pp. 17-18, 2012. View at Google Scholar
  13. H. Y. Wang, “Curative effect evaluation of mongolian medicine garidisan in 90 patients with ulcerative colitis,” Asia-Pacific Traditional Medicine, vol. 10, no. 15, pp. 11-12, 2014. View at Google Scholar
  14. T. Arakawa, T. Watanabe, T. Tanigawa, K. Tominaga, Y. Fujiwara, and K. Morimoto, “Quality of ulcer healing in gastrointestinal tract: its pathophysiology and clinical relevance,” World Journal of Gastroenterology, vol. 18, no. 35, pp. 4811–4822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Arakawa and K. Kobayashi, “Quality of ulcer healing-a new concept to rank healed peptic ulcers,” Gastroenterologia Japonica, vol. 28, no. 5, pp. 158–162, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. C. P. Boal, de Castro F. D., B. Rosa, M. J. Moreira, and J. Cotter, “Mucosal healing in ulcerative colitis-when zero is better,” Journal of Crohn's and Colitis, vol. 10, pp. 20–25, 2016. View at Google Scholar
  17. H. S. Cooper, S. N. Murthy, R. S. Shah, and D. J. Sedergran, “Clinicopathologic study of dextran sulfate sodium experimental murine colitis,” Laboratory Investigation, vol. 69, no. 2, pp. 238–249, 1993. View at Google Scholar
  18. A. P. Paiotti, D. A. Ribeiro, R. M. Silva et al., “Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in wistar rats,” Journal of Molecular Histology, vol. 43, no. 3, pp. 307–317, 2012. View at Google Scholar
  19. A. D. Millar, D. S. Rampton, C. L. Chander et al., “Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis,” Gut, vol. 39, no. 3, pp. 407–415, 1996. View at Google Scholar
  20. S. Fichtner-Feigl, I. J. Fuss, C. A. Young et al., “Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2, 4, 6-trinitrobenzene sulfonic acid colitis,” Journal of Immunology, vol. 178, pp. 5859–5870, 2007. View at Google Scholar
  21. G. Tolstanova, T. Khomenko, X. Deng, S. Szabo, and Z. Sandor, “New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis,” Biochemical and Biophysical Research Communications, vol. 399, no. 4, pp. 613–616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Tarnawski and A. Ahluwalia, “Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers,” Current Medicinal Chemistry, vol. 19, no. 1, pp. 16–27, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Szabo, Z. Gombos, and Z. Sandor, “Growth factors in gastrointestinal diseases,” BioDrugs, vol. 12, no. 1, pp. 27–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. K. A. Oikonomou, A. N. Kapsoritakis, A. I. Kapsoritaki, A. C. Manolakis, F. D. Tsiopoulos, A. E. Germenis et al., “Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage,” Growth Factors, vol. 28, pp. 461–466, 2010. View at Google Scholar
  25. C. Ippolito, R. Colucci, C. Segnani et al., “Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative,” Journal of Crohn's and Colitis, vol. 10, pp. 1194–1204, 2016. View at Google Scholar
  26. X. Wang, J. Zhao, Z. Han, and F. Tang, “Protective effects of semen crotonis pulveratum on trinitrobenzene sulphonic acid-induced colitis in rats and H2O2-induced intestinal cell apoptosis in vitro,” International Journal of Molecular Medicine, vol. 35, pp. 1699–1707, 2015. View at Google Scholar
  27. R. Sumagin, A. Z. Robin, A. Nusrat, and C. A. Parkos, “Transmigrated neutrophils in the intestinal lumen engage ICAM-1 to regulate the epithelial barrier and neutrophil recruitment,” Mucosal Immunology, vol. 7, no. 4, pp. 905–915, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Wang, X. Xuan, L. Wang et al., “Expression and correlation analysis between inflammatory cytokines and calprotectin in the rat model of ulcerative colitis,” Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 30, no. 3, pp. 278–283, 2014. View at Google Scholar · View at Scopus
  29. M. Floer, M. Götte, M. K. Wild et al., “Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice,” American Journal of Pathology, vol. 176, no. 1, pp. 146–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. D. M. Abdallah and N. R. Ismael, “Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats,” Canadian Journal of Physiology and Pharmacology, vol. 89, pp. 811–818, 2011. View at Google Scholar
  31. J. R. Philpott and P. B. Miner Jr., “Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD,” Expert Opinion on Biological Therapy, vol. 8, no. 10, pp. 1627–1632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. A. Postovalova, D. N. Khochansky, N. A. Zolotova, Y. Gao, O. V. Makarova, and M. T. Dobrynina, “Morphological changes in mesenteric lymph nodes and lymphocyte subpopulation composition in experimental ulcerative colitis,” Bulletin of Experimental Biology and Medicine, vol. 160, pp. 835–839, 2016. View at Google Scholar
  33. X. Liu, Q. Ouyang, L. Huang, H. Ma, R. Hu, and Y. Zhang, “Isolation and phenotypic analysis of lamina propria mononuclear cells from colonoscopic biopsy specimens,” Hua Xi Yi Ke Da Xue Xue Bao, vol. 31, pp. 116–118, 2000. View at Google Scholar
  34. S. B. Hanauer, “Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities,” Inflammatory Bowel Diseases, vol. 12, supplement 1, pp. S3–S9, 2006. View at Publisher · View at Google Scholar · View at Scopus